Knowledge, attitudes and perceptions of healthcare professionals and patients towards biosimilars in Singapore

ObjectiveBiosimilars offer a cost-effective alternative to biologics. Despite high (>95%) adoption in Singapore, gaps remain in healthcare professionals' (HCPs) and patients' knowledge and confidence. This study aims to assess the knowledge, attitudes and perceptions (KAP) of HCPs and patients regarding biosimilars in Singapore, identifying barriers and facilitators to their uptake.MethodsA cross-sectional survey was conducted among HCPs within SingHealth institutions and patients receiving biologic/biosimilar treatment at National Cancer Centre Singapore (NCCS) from February to April 2025. Validated questionnaires were administered electronically, and data were analyzed using descriptive, bivariate and multivariate methods using IBM SPSS Statistics 30.0.ResultsA total of 111 HCPs and 202 patients were surveyed. HCPs demonstrated moderate knowledge (60.8%) and confidence (59%) but generally positive attitudes. Patients showed limited knowledge (15.7%), generally neutral attitudes, and low confidence (35%). Occupation was the strongest predictor of HCPs' knowledge, attitudes, and confidence, while higher education was associated with greater patient knowledge. HCPs confidence in efficacy was independently predicted by knowledge (aOR = 1.18), while confidence in safety was linked to attitudes (aOR = 1.34). For patients, higher knowledge correlated with greater safety confidence (p < 0.05).ConclusionInstitutional mandates ensure strong biosimilar adoption, yet HCPs require further education to strengthen foundational understanding. For patients, low awareness and confidence are key barriers. Enhancing education and capitalising on the high levels of trust in HCPs may support transparent and confident decision-making in biosimilar use.